BBC news report -- Multiplex screening for bowel and colorectal cancer

Simultaneously detect 28 common mutations in 4 genes in three stool samples within 48 hours
Colorectal Cancer, or Bowel Cancer, is the second largest cause of cancer mortality in the Western world. However, it is also among the most curable cancers when detected early. With regular screening from 50 years, pre-cancerous lesions and polyps can be detected and removed before they can become cancerous. This highlights the importance of colorectal cancer screening for early detection.
Stool DNA (sDNA) screening offers a non-invasive yet highly specific screening method to identify high risk individuals that would benefit from a colonoscopy. The Ranplex CRC Array tests colorectal cells that have been shed into the stool, for 28 mutations that are common in colorectal cancer and pre-cancerous growths. The screening test is performed on a single stool sample, without the need for any patient preparation. Find out more at http://www.randox.com

Colorectal Cancer Detection
Current methods of colorectal cancer detection can be indirect or direct. Each
method has its advantages and disadvantages. Faecal occult blood testing is a non-invasive and inexpensive indirect detection method. However, it suffers from low sensitivity and specificity, since tumours do not always bleed continuously and other conditions can cause faecal blood. Barium enemas, flexible sigmoidoscopy and colonoscopy are invasive direct detection methods with complex patient preparation, such as a clear liquid diet, laxative use and warm water enemas. These methods have good sensitivity and specificity but poor patient compliance. It can be difficult to identify pre- cancerous lesions and tumors by colonoscopy. Faecal DNA testing may allow identification of mutations associated with colorectal cancer resulting in earlier
detection and better patient prognosis.
Non Invasive detection of Colorectal Cancer
Colorectal cells are continuously shed into the stool. DNA is stable in stool,
facilitating the detection of mutations in cells shed from the whole length of the
colorectum. RanplexCRC detects wild-type DNA and the following mutations in stool. A single stool specimen is required with no dietary restrictions or medication changes. RanplexCRC can also be used to compare patient DNA from stool and matched tissue samples. RanplexCRC is for research use only. Find out more at http://www.randox.com

Category:

Science & Technology

Tags:

• BBC
• technology
• cancer
• clinical
• diagnostics
• laboratory
• screening
• colorectal bowel

[smahmed1234]

Nice. Will see more latter. Thanks